Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 3, 2020updated 09 Sep 2020 3:07pm

Biorasi selects IBM to expand clinical trial execution capabilities

Contract research organisation (CRO) Biorasi has selected IBM Watson Health (IBM) as a preferred vendor to expand its capabilities and management in the execution of clinical trials.

Contract research organisation (CRO) Biorasi has selected IBM Watson Health (IBM) as a preferred vendor to expand its capabilities and management in the execution of clinical trials.

Biorasi will expand its capabilities by leveraging IBM’s Clinical Development (ICD) platform, a clinical data management system (CDMS) designed to accelerate the trial process.

Biorasi Data Sciences and Biometrics senior director Roberto Silberwasser said: “The collaboration with IBM Watson Health spotlights our vital business relationship and the innovative capabilities of the ICD solution.

“IBM’s technology solutions not only complement Biorasi’s core competencies as a CRO, but those of other preferred vendors as well.”

The single-instance, fully-integrated, SaaS CDMS ICD means the cycle time to start, amend, and manage clinical studies can be reduced.

Trial sponsors and clinical site staff will be able to centralise and organise information and minimise the time and cost for clinical trials.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

By serving as a flexible and scalable data management platform, the ICD platform will help design and manage clinical trials by incorporating optional features specific to clinical trials.

A previous clinical study revealed that Biorasi could reduce the database build time by 25% and overall project costs by more than half by leveraging ICD’s capabilities.

IBM Watson Health Life Sciences vice-president Mary Varghese Presti said: “We are moving into a new era of clinical development as the Covid-19 crisis has reinforced the desperate need to find meaningful ways to help accelerate the clinical trial process.

“We are proud to support Biorasi’s ongoing effort to bring greater efficiency and precision to the clinical trial process, particularly in emerging areas such as digital therapeutics, virtual trials and rescue studies.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU